# Partnering

We believe bringing successful new therapies to patients in IO and I&I diseases requires more than innovation — it takes exceptional partnerships. By combining our expertise with like-minded partners, we work to deliver effective, life-changing medicines to patients worldwide.

### Collaborating to Transform Treatments

We seek to collaborate with partners to advance our IO and I&I portfolio of targeted therapies

1. Out-license of select pipeline assets from discovery to clinical programs
2. Co-development of internal pipeline assets
3. Collaborations to explore novel & innovative technologies
4. Expansion of our disease cell atlas and translational technologies

Please send any inquiries by email to: **[bd@hifibio.com](mailto:bd@hifibio.com)**

### IO Programs Available for Partnership

| Program | Discovery | Preclinical (IND) | Phase I | Phase II/III |
| --- | --- | --- | --- | --- |
| Immuno-oncology |
| [HFB200603*](/content/pipeline/programs/hfb200603/index.html) BTLA Antagonist |  |
| [Emunkitug* (HFB200301)](/content/pipeline/programs/hfb200301/index.html) TNFR2 Agonist |  |
| [Nuvustotug (HFB301001)](/content/pipeline/programs/hfb301001/index.html) OX40 Agonist |  |
| HFB200902 Gal-9 Antagonist |  |
| HFB101110 CCR8 Depletor |  |
| Immunology & Inflammation |
| [HFB200604](/content/pipeline/programs/hfb200604/index.html) BTLA Agonist |  |
| HFB100204 CXCR5 Depletor |  |
| [HFB3024](/content/pipeline/programs/hfb3024/index.html) KLRG1 Depletor |  |
| HFB2025 PD-1 Depletor |  |
| HFB2027 TNFR2 Agonist |  |
| Bispecifics Novel targets |  |

**** As monotherapy or in combination with anti-PD-1, Tislelizumab, supply agreement with Novartis

## Publications

HFB200301

HFB200603

HFB301001

Other IO Programs

|  |  | Sep 25, 2025 |
| --- | --- | --- |
| [**HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO)**](/content/hifibio-therapeutics-to-present-updated-phase-1-clinical-data-of-two-immuno-oncology-programs-at-the-2025-annual-meeting-of-the-european-society-for-medical-oncology-esmo/index.html) |
| Society for Immunotherapy of Cancer 
| Poster 
| Nov 08, 2024 |
| [**Predictive and generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: Drug Intelligence Science (DIS®)**](/content/wp-content/uploads/2024/11/HFB200301-SITC-2024.Final-1.pdf) |
| European Society for Medical Oncology 
| Poster 
| Sep 14, 2024 |
| [**Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody, in monotherapy and in combination with the anti-PD-1 tislelizumab in patients with advanced solid tumors**](/content/wp-content/uploads/2024/09/HFB200301-ESMO-2024-Poster.pdf) |
| American Society of Clinical Oncology 
| Poster 
| Jun 01, 2024 |
| [**Phase I Dose Escalation Trial of the First-in-Class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in adult Patients with Advanced Solid Tumors**](/content/wp-content/uploads/2024/07/HFB200301-Poster-ASCO-2024-FINAL-VERSION.pdf) |
| American Association for Cancer Research 
| Poster 
| Apr 10, 2024 |
| [**Optimization of T cell Co-Stimulatory Agonists: A Semi-Mechanistic PKPD Model Integrating Drug Properties and Tumor-Immune Interactions**](/content/wp-content/uploads/2024/07/PKPD-Model-AACR-2024-Poster-Final.pdf) |
| American Society of Clinical Oncology 
| Poster 
| Apr 27, 2022 |
| [**Phase I Study of HFB200301, a First-in-Class TNFR2 Agonist Monoclonal Antibody in Patients with Solid Tumors Selected via Drug Intelligent Science (DIS™)**](/content/wp-content/uploads/2024/07/HFB200301-ASCO-2022-Poster.pdf) |
| American Association for Cancer Research 
| Presentation  
| Apr 12, 2021 |
| [**Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer**](https://iframe.dacast.com/vod/2b8dfb35-e9a6-dc81-e7ed-4a819fc143b4/d0d06e6c-f45d-4642-b604-d6480d9a1898) |
| American Association for Cancer Research 
| Poster 
| Jul 03, 2020 |
| [**Discovery and Characterization of Novel TNFR2 Antibodies to Modulate T Cell Activities in Immunosuppressive Environment**](/content/wp-content/uploads/2024/07/HFB200301-AACR-2020-Poster.pdf) |

## Related News

[**Apr 16, 2024 HiFiBiO Therapeutics Receives Grant to Research Long COVID and ME/CFS in Collaboration with UMass Chan Medical School**](/content/hifibio-therapeutics-receives-grant-to-research-long-covid-and-me-cfs-in-collaboration-with-umass-chan-medical-school/index.html)

[**Dec 20, 2021 FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program**](/content/fibrogen-exercises-exclusive-license-option-for-hifibios-ccr8-program/index.html)

[**Jun 17, 2021 FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease**](/content/fibrogen-and-hifibio-announce-transformative-partnership-to-advance-next-generation-therapies-for-patients-with-cancer-and-autoimmune-disease/index.html)